ALN-BCAT Investigational RNAi therapy undergoing Phase 1 clinical development for hepatocellular carcinoma, extending Alnylam’s gene-silencing portfolio into primary liver cancer.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-BCAT.
Add it to your Products I use list and share why you use it.